Obesity Treatments
3 articles on Obesity Treatments, written by Shotlee and medically reviewed for clinical accuracy.
China's Pharma Dominance Is Just Beginning
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
5 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
Roche Allocates $100 Million in Structure Licensing Pact to Bolster GLP-1 Standpoint
Roche has invested $100 million in a licensing agreement with Structure Therapeutics to protect its GLP-1 portfolio from patent challenges. The deal covers CT-996, an oral GLP-1 medication acquired from Carmot, and includes royalties on future sales. Analysts highlight how this move reinforces Structure's strong intellectual property in GLP-1 agonists.
3 min read